Eli Lilly and its subsidiary, Avid Radiopharmaceuticals, have announced that the European Commission has approved Amyvid (Florbetapir (18F)) solution for injection as a diagnostic radiopharmaceutical.

Objectives Recent reports suggest that florbetapir F18 (AV-45) is a new PET imaging agent targeting Aβ aggregates in the brain of patient with Alzheimer’s disease. Similarly, accumulation of Aβ ...